Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tom pope who wrote (165)	12/7/2003 3:32:38 PM
From: Icebrg	Read Replies (1) of 946

Tom As long as the IP situation has not been settled Trisenox is in no-mans land. The present Orphan Drug Status only gives protection until 2008. Any additional indication they may obtain ODS for, will give them an additional 3 years - for that indication. But I guess that as soon as arsenic trioxide becomes available in a generic format these additional years will not be of much help. If however they are issued a patent - as Bianco indicates will happen relatively soon - Trisenox will become an interesting drug with many different application possibilities. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next